VYNE News and Press, VYNE Therapeutics Inc Com From 10/07/20

VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts Coverage Effective October 2, 2020 on Express Scripts National Preferred, Flex, and Basic Formularies PR Newswire BRIDGEWATER, N.J., Oct. 7, 2020 BRIDGEWATER, N.J. ...

VYNE Therapeutics (VYNE) is up 10% after H.C. Wainwright reiterated its Buy rating and boosted its price target on ZILXI's (minocycline) entry to U.S. pharmaceutical market.The firm raised its price target to $3.50 from $3, implying an approximately 17% upside. Analyst Oren Liv...

VYNE Therapeutics (VYNE) announces that its novel ZILXI (minocycline) topical foam, 1.5% is now available by prescription for the treatment of inflammatory lesions of rosacea in adults.This new once-daily therapy will be available in retail, community and specialty pharmacies nationwide. The ...

VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI Offers Efficacy with Low Syst...

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults ZILXI Offers Efficacy with Low Systemic Absorption BRIDGEWATER, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq...

Since the time of my last article, Vyne's market cap has dropped from $330 million to just $285 million. Despite a slowdown in the Amzeeq launch due to the pandemic, sales seem to be picking back up and the long-term trajectory remains strong. Vyne looks substantially undervalued ...

BRIDGEWATER, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Company will host a physician symposium on AMZEEQ ® and ZILXI™ on Thursday, October 1, 2020 from 12pm &#...

The following slide deck was published by VYNE Therapeutics Inc. in conjunction with this Read more ...